Veloxis Insiders Knew Better: Yet Only One Came Forward | PharmaVoice

Veloxis has agreed to pay more than $46 million to resolve criminal and civil charges that it used sham consulting arrangements, improper pharmacy payments, lavish meals, alcohol, luxury resort stays, to get its drug on formulary, on protocols, and get patients switched to Envarsus XR, its kidney-transplant immunosuppression drug.

The qui tam complaint, filed in 2020, alleged that Veloxis and its employees began this campaign in 2016, and that the company concealed improper payments through falsified expense reports and inaccurate Open Payments reporting.

The resolution includes a criminal penalty of about $10.04 million, a three-year deferred prosecution agreement under which the company admitted to numerous acts violating the antikickback statute, a $34.45 million civil settlement with the United States and participating states, and a $1.55 million civil penalty tied to Sunshine Act reporting failures – the law that requires drug and medical device companies to reveal what doctors and institutions they pay as part of their business program.

Veloxis targeted influential transplant professionals and specialty pharmacies to drive formulary access, protocol placement, prescriptions, and purchases of Envarsus, including against lower-cost generic competition, while disguising improper payments as advisory-board activity, consulting work, and “enhanced services.”

“This case is a reminder that insiders matter, they often see the truth long before the government does. Conduct that is “normalized” internally but breaks the law can be halted if insiders come forward, protect themselves, and help the government stop it” said one of the whistleblowers’ lawyers, Mark Kleiman, himself a former healthcare whistleblower.

His partner, Pooja Rajaram added: “People inside pharmaceutical and healthcare companies should understand that they are not powerless. When a company pressures employees to look the other way, disguise payments, or treat kickbacks as just part of hitting the numbers, someone can step forward, tell the truth, and make a real difference.” 

Phillips & Cohen attorneys Erika Kelton and Emily Stabile were also instrumental in achieving this victory.  Kelton added: “The Veloxis resolution shows that pharma company misconduct recast as market access or strategy is still illegal and can be stopped by knowledgeable insiders who are willing to step forward.”